ALK and neoplasm: Previous studies reported that patients with EGFR, ALK, ROS1, and RET mutations carry relatively low tumor mutation burden (TMB) (3–6 mutations/Mb, 2–4 mutations/Mb, 4 mutations/Mb, and 4.8 mutations/Mb, respectively)33,34.